Evaluation of COVID-19 vaccines in primary prevention against infections and reduction in severity of illness following the outbreak of SARS-CoV-2 omicron variant in Shanghai

ObjectivesTo evaluate COVID-19 vaccines in primary prevention against infections and lessen the severity of illness following the most recent outbreak of the SARS-CoV-2 Omicron variant in Shanghai.Data sourcesData from 153,544 COVID-19 patients admitted to the Shanghai “Four-Leaf Clover” Fangcang makeshift shelter hospital were collected using a structured electronic questionnaire, which was then merged with electronic medical records of the hospital. For healthy controls, data on vaccination status and other information were obtained from 228 community-based residents, using the same structured electronic questionnaire.MethodsTo investigate whether inactivated vaccines were effective in protecting against SARS-CoV-2 virus, we estimated the odds ratio (OR) of the vaccination by comparing cases and matched community-based healthy controls. To evaluate the potential benefits of vaccination in lowering the risk of symptomatic infection (vs. asymptomatic), we estimated the relative risk (RR) of symptomatic infections among diagnosed patients. We also applied multivariate stepwise logistic regression analyses to measure the risk of disease severity (symptomatic vs. asymptomatic and moderate/severe vs. mild) in the COVID-19 patient cohort with vaccination status as an independent variable while controlling for potential confounding factors.ResultsOf the 153,544 COVID-19 patients included in the analysis, the mean age was 41.59 years and 90,830 were males (59.2%). Of the study cohort, 118,124 patients had been vaccinated (76.9%) and 143,225 were asymptomatic patients (93.3%). Of the 10,319 symptomatic patients, 10,031 (97.2%), 281 (2.7%), and 7 (0.1%) experienced mild, moderate, and severe infections, respectively. Hypertension (8.7%) and diabetes (3.0%) accounted for the majority of comorbidities. There is no evidence that the vaccination helped protect from infections (OR = 0.82, p = 0.613). Vaccination, however, offered a small but significant protection against symptomatic infections (RR = 0.92, p < 0.001) and halved the risk of moderate/severe infections (OR = 0.48, 95% CI: 0.37–0.61). Older age (≥60 years) and malignant tumors were significantly associated with moderate/severe infections.ConclusionInactivated COVID-19 vaccines helped provide small but significant protection against symptomatic infections and halved the risk of moderate/severe illness among symptomatic patients. The vaccination was not effective in blocking the SARS-CoV-2 Omicron Variant community spread..

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:10
Enthalten in:	Frontiers in Medicine - 10(2023)

Sprache:	Englisch

Beteiligte Personen:

Dawei Yang [VerfasserIn] Dawei Yang [VerfasserIn] Huifen Weng [VerfasserIn] Rui Wang [VerfasserIn] You Li [VerfasserIn] Hao Zhang [VerfasserIn] Shifeng Shao [VerfasserIn] Hunan Huang [VerfasserIn] Yuanlin Song [VerfasserIn] Yuanlin Song [VerfasserIn] Yuanlin Song [VerfasserIn] Xiaoyan Chen [VerfasserIn] Xiaoyan Chen [VerfasserIn] Dongni Hou [VerfasserIn] Dongni Hou [VerfasserIn] Yin Wu [VerfasserIn] Xingwei Lu [VerfasserIn] Wei Yang [VerfasserIn] Zhengguo Chen [VerfasserIn] Xiaohan Hu [VerfasserIn] Jianwei Xuan [VerfasserIn] Chunxue Bai [VerfasserIn] Chunxue Bai [VerfasserIn] Yaoli Wang [VerfasserIn]

Links:	doi.org [kostenfrei] doaj.org [kostenfrei] www.frontiersin.org [kostenfrei] Journal toc [kostenfrei]

Themen:	COVID-19 Epidemiology Health policy Medicine (General) Public health Respiratory tract infections Vaccines

doi:	10.3389/fmed.2023.1079165

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	DOAJ080833195